- Home
- STRO vs CELU Comparison
STRO vs CELU Comparison
Compare STRO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CELU
- Stock Information
- Founded
- STRO 2003
- CELU 2016
- Country
- STRO United States
- CELU United States
- Employees
- STRO N/A
- CELU N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- CELU Health Care
- Exchange
- STRO Nasdaq
- CELU Nasdaq
- Market Cap
- STRO 69.1M
- CELU 64.3M
- IPO Year
- STRO 2018
- CELU N/A
- Fundamental
- Price
- STRO $0.97
- CELU $2.26
- Analyst Decision
- STRO Hold
- CELU Strong Buy
- Analyst Count
- STRO 7
- CELU 1
- Target Price
- STRO $1.97
- CELU $6.00
- AVG Volume (30 Days)
- STRO 553.4K
- CELU 122.1K
- Earning Date
- STRO 08-07-2025
- CELU 08-29-2025
- Dividend Yield
- STRO N/A
- CELU N/A
- EPS Growth
- STRO N/A
- CELU N/A
- EPS
- STRO N/A
- CELU N/A
- Revenue
- STRO $104,473,000.00
- CELU $44,590,000.00
- Revenue This Year
- STRO $65.42
- CELU $23.29
- Revenue Next Year
- STRO N/A
- CELU N/A
- P/E Ratio
- STRO N/A
- CELU N/A
- Revenue Growth
- STRO N/A
- CELU 4.45
- 52 Week Low
- STRO $0.52
- CELU $1.00
- 52 Week High
- STRO $4.80
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- STRO 58.41
- CELU 35.61
- Support Level
- STRO $0.90
- CELU $2.02
- Resistance Level
- STRO $1.18
- CELU $4.00
- Average True Range (ATR)
- STRO 0.09
- CELU 0.30
- MACD
- STRO 0.01
- CELU -0.21
- Stochastic Oscillator
- STRO 43.43
- CELU 12.06
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.